BOSTON, Nov. 17, 2005 — Inotek Pharmaceuticals Corporation today announced that it has closed its Series B financing with the completion of raising the second $10 million. In total, the Company raised $35 million in its Series B round.
Mitchell Bloom, partner, and associates David Cappillo, Matthew Rowe and Kevin Shnier from Goodwin Procter LLP represented Inotek in this transaction.